Sun’s Rise in the West, A Deal That’s Priced Right, But R&D Remains the Missing Piece
Sun Pharma would appear to have got itself a sweet deal when it agreed to acquire all outstanding shares of US-based Organon for 3.7billionincashat14 per share. The US pharma company had outstanding debt of 8.6billionattheendof2025,annualsalesof6.2 billion and adjusted EBITDA of 1.9billion.Itsenterprisevalueof11.75 billion, as widely reported, is the sum of its stock value and debt, less cash on hand. While its price-earnings ratio (a more common yardstick) goes by net income and not EBITDA, the latter calculated per share makes it clear that Sun is paying a competitive price for this maker of assorted healthcare products focused on women’s health and some biosimilars. The company has marketing channels in 140 countries that Sun gets to snap up, apart from production centres in the UK, Netherlands, Belgium, Indonesia, Brazil and Mexico. This acquisition makes sound commercial sense and catapults Sun into the global league of pharma players. However, a slight let-down is that it does not give Sun much R&D muscle. The missing piece is innovation. For a company that has built its fortune on generics and legacy drugs, the next frontier must be high-risk, high-return drug discovery. And for that, Sun may need to look elsewhere.
The Financials: A Bargain Price for Global Expansion
Organon was spun off from Merck in 2021. Merck wanted to focus on finding new therapies and vaccines—on innovation, on R&D, on the high-risk, high-reward business of drug discovery. Organon was the legacy business: established brands, women’s health products, biosimilars, and a portfolio of drugs that are off-patent or nearing patent expiry. It is a cash-generating machine, but not a growth engine.
Sun is buying a subsidiary for legacy drugs that was cleaved apart and listed separately. The price is competitive. The enterprise value of $11.75 billion represents about 6.2 times Organon’s annual sales, or about 6.2 times adjusted EBITDA. For a company with stable cash flows, low growth, but strong market positions, this is a reasonable multiple. More importantly, Sun gets immediate access to Organon’s marketing channels in 140 countries. It takes years for a company to build such a network organically—hiring sales teams, negotiating with distributors, registering products with regulators. Sun gets it overnight. It also gets manufacturing facilities in the UK, Netherlands, Belgium, Indonesia, Brazil, and Mexico. These are not just cost centres; they are strategic assets that give Sun local production, local regulatory approvals, and local market access.
Organon does not have a plant in the US. This is notable because the US has imposed a 100 per cent import tariff on patented drugs (a protectionist measure to encourage domestic manufacturing). Sun already has some manufacturing capacity in the US and could expand that to qualify for duty exemptions, helped along perhaps by Organon’s antecedents. Since Organon was once part of Merck, its products are already approved and accepted in the US market. Sun can leverage that acceptance while shifting production to its own US facilities.
The R&D Gap: What Sun Is Not Getting
The reason Merck spun Organon out of itself was that it wanted to focus on finding new therapies and vaccines. Sun is buying a subsidiary for legacy drugs. This is not a criticism; it is a description. Sun is a generics company that has built its success on low-cost, high-volume production of off-patent drugs. It has not been a leader in innovation. The acquisition of Organon does not change that. Organon spends a modest amount on R&D—around $200-300 million annually, or about 3-5 per cent of sales. This is typical for a legacy pharma company. But it is far below the 15-20 per cent spent by innovative pharma companies like Merck, Pfizer, or Roche.
Sun could leverage its latest acquisition to lay fresh emphasis on innovation. It now has the scale, the cash flow, and the global footprint to invest in R&D. It has access to Organon’s research team, its early-stage pipeline, and its relationships with academic institutions. But the acquisition itself does not bring a blockbuster drug or a breakthrough therapy. That will have to be built organically or bought through another deal.
The AI Revolution in Drug Discovery: A Missed Opportunity?
With specialised AI tools such as AlphaFold having figured out the likely shapes of over 200 million proteins, drug discovery has become far simpler than it has long been. AlphaFold, developed by DeepMind (a Google subsidiary), can predict the 3D structure of proteins from their amino acid sequences with remarkable accuracy. This was previously a slow, expensive, trial-and-error process. Now it can be done in minutes.
This is a game-changer for drug discovery. Most drugs work by binding to a specific protein and altering its function. Knowing the shape of the protein allows researchers to design molecules that fit perfectly, like a key in a lock. This was previously done through high-throughput screening—testing millions of compounds blindly in the hope that one might work. Now it can be done computationally.
China has been making rapid gains in the field of advanced therapies, with Western pharma companies now buying marketing and drug-trial licences from Chinese ones. Chinese biotech firms have developed novel therapies for cancer, autoimmune diseases, and genetic disorders. Western companies are paying billions for the rights to these drugs. China is no longer just a manufacturer of generics; it is becoming an innovator.
It is high time India played a more active role in advancing the frontier of medicine. With genomic data and AI, gene-adapted therapies are an emerging opportunity for a country of India’s genetic diversity. India has a population of 1.4 billion, with thousands of distinct ethnic groups, each with its own genetic variations. This diversity is a goldmine for understanding how genes affect disease risk and drug response. Gene-adapted therapies—treatments tailored to a patient’s genetic profile—are the future of medicine. India could be a leader in this field, but it requires investment in genomic sequencing, bioinformatics, and clinical trials.
The Financial Services Gap: Where Are the Indian Banks?
A feature of Sun’s snap-up of Organon is the minimal role played by Indian entities in the financial services used for the deal and also the acquisition finance going into it. As reported by Bloomberg, JPMorgan and Jefferies acted as financial advisors to Sun Pharma, which turned to Citigroup, JPMorgan and Mitsubishi UFJ for funds. Loans will reportedly finance a chunk of it, with Sun using cash on hand too. Organon’s lead financial advisor was Morgan Stanley, with added advice from Goldman Sachs.
Many of these financial companies have lots of Indians on their rolls, experts at structuring buyout deals, but somehow Indian firms have not yet broken into the league of cross-border acquisitions. Indian banks are large—State Bank of India, HDFC Bank, ICICI Bank are among the largest in the world by market capitalisation. But they lack the cross-border expertise, the global networks, and the risk appetite to advise on or finance multi-billion dollar acquisitions. Indian investment banks are even smaller.
This should change as Indian companies look overseas for targets. Indian firms are sitting on large cash balances. They are looking to expand globally. They will need financial services: advice on valuation, due diligence, deal structuring, financing, and risk management. Indian banks and investment banks should be positioning themselves to provide these services. They will need to hire global talent, build cross-border capabilities, and form alliances with international partners. The Sun-Organon deal is a wake-up call: if Indian banks do not step up, they will be left behind.
The Road Ahead: More Deals, Perhaps R&D Too
Globally, there may be other deals waiting to be done in the pharma space. The industry is consolidating. Large pharma companies are spinning off legacy businesses to focus on innovation. Generic drugmakers are looking to acquire scale and global reach. Indian drugmakers might want to follow Sun’s lead. Overnight presence in multiple markets could tempt others looking for inorganic expansion. In time, maybe we can expect the odd high-risk, high-return R&D play too.
The Sun-Organon deal is a milestone. It is the largest cross-border acquisition by an Indian pharma company, and one of the largest by any Indian company. It catapults Sun into the global league. But it is also a reminder of what India lacks: innovation, R&D, and a financial services industry capable of supporting global ambitions. The deal is priced right. Now Sun must make the next move.
Q&A: Sun Pharma’s Acquisition of Organon
Q1: What are the key financial terms of Sun Pharma’s acquisition of Organon, and why is it considered a “bargain”?
A1: Sun Pharma agreed to acquire all outstanding shares of US-based Organon for 3.7billionincashat14 per share. Organon had outstanding debt of 8.6billion,annualsalesof6.2 billion, and adjusted EBITDA of 1.9billion.Itsenterprisevalueis11.75 billion (stock value + debt – cash). The article states that Sun is paying a “competitive price” for this maker of women’s health products and biosimilars. The bargain lies in what Sun acquires: marketing channels in 140 countries, production centres in the UK, Netherlands, Belgium, Indonesia, Brazil, and Mexico, and a blue-chip American lineage (spun off from Merck in 2021). Sun gets “overnight presence in multiple markets” that would take years to build organically. Organon does not have a US plant, but Sun already has US manufacturing capacity and could expand it to qualify for duty exemptions from 100% US import tariffs on patented drugs.
Q2: What is the “R&D gap” in the acquisition, and why is it significant?
A2: The article notes that the “slight let-down is that it does not give Sun much R&D muscle.” Organon spends only about $200-300 million annually on R&D (3-5 per cent of sales) , far below the 15-20 per cent spent by innovative pharma companies like Merck, Pfizer, or Roche. The reason Merck spun Organon off was to focus on “finding new therapies and vaccines.” Sun is buying a “subsidiary for legacy drugs.” The article argues that Sun “should leverage its latest acquisition to lay fresh emphasis on innovation,” but the acquisition itself does not bring a blockbuster drug or breakthrough therapy. “That will have to be built organically or bought through another deal.”
Q3: How is AI transforming drug discovery, and what opportunity is India missing?
A3: AI tools such as AlphaFold (developed by DeepMind) have figured out the likely shapes of over 200 million proteins, making drug discovery “far simpler than it has long been.” Previously, determining protein structures was a slow, expensive, trial-and-error process; now it can be done computationally in minutes. Most drugs work by binding to specific proteins; knowing protein shapes allows researchers to design molecules that fit perfectly. The article notes that China has been making “rapid gains” in advanced therapies, with Western pharma companies now buying marketing and drug-trial licences from Chinese firms. It is “high time India played a more active role in advancing the frontier of medicine.” With genomic data and AI, gene-adapted therapies are an emerging opportunity for a country of India’s “genetic diversity.” India could be a leader in this field, but it requires investment in genomic sequencing, bioinformatics, and clinical trials.
Q4: What role did Indian financial institutions play in the Sun-Organon deal, and what does this reveal?
A4: The article notes the “minimal role played by Indian entities” in the financial services used for the deal. JPMorgan and Jefferies acted as financial advisors to Sun Pharma, which turned to Citigroup, JPMorgan, and Mitsubishi UFJ for funds. Organon’s lead financial advisor was Morgan Stanley, with added advice from Goldman Sachs. While “many of these financial companies have lots of Indians on their rolls, experts at structuring buyout deals,” Indian firms have not yet “broken into the league of cross-border acquisitions.” The article argues that this should change as Indian companies look overseas for targets. Indian banks are large (SBI, HDFC, ICICI) but “lack the cross-border expertise, the global networks, and the risk appetite” to advise on or finance multi-billion dollar acquisitions. The Sun-Organon deal is a “wake-up call” for Indian banks to build global capabilities.
Q5: What is the article’s overall assessment of the Sun-Organon deal and its implications for Indian pharma?
A5: The article assesses the deal as a “sweet deal” that “makes sound commercial sense and catapults Sun into the global league of pharma players.” However, the missing piece is innovation and R&D. The acquisition gives Sun global scale (140 countries, multiple manufacturing sites) but not breakthrough drugs. The article suggests that with AI transforming drug discovery, “India should play a more active role in advancing the frontier of medicine.” It notes that “China has been making rapid gains” while India lags. The article also notes the “minimal role” of Indian financial institutions in the deal, calling it a gap that needs to be filled. It concludes that “globally, there may be other deals waiting to be done in the pharma space” and that “other Indian drugmakers might want to follow Sun’s lead.” It ends with a hopeful note: “In time, maybe we can expect the odd high-risk, high-return R&D play too.” The deal is “priced right,” but “now Sun must make the next move.”
